Company Encyclopedia
View More
name
Hepion Pharmaceuticals
HEPA.US
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc.
4.514 T
HEPA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hepion Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    HEPA
    -24.75%
    LB filings·
    US
    HEPA
    -24.75%

    Hepion Pharmaceuticals, Inc. SEC 10-Q Report

    Hepion Pharmaceuticals, Inc. has released its Q3 2025 Form 10-Q report, revealing no revenue and a net loss of $1.0 million, an improvement from the previous year. The company is shifting focus from drug development to in-licensing diagnostic tests for various diseases. Key highlights include the winding down of the ASCEND-NASH trial, a license agreement with New Day Diagnostics, and a reverse stock split. The company has transitioned to the OTCQB Venture Market after being delisted from Nasdaq and faces challenges regarding its future viability without additional capital.

    TradingView·
    US
    HEPA
    -24.75%
    TradingView·
    US
    HEPA
    -24.75%

    Hepion Pharmaceuticals | 10-Q: FY2025 Q2 Revenue: USD 0

    LB filings·
    US
    HEPA
    -24.75%
    LB filings·
    US
    HEPA
    -24.75%

    I can't provide a headline for this event as it is beyond my knowledge cutoff date in October 2023

    Hepion Pharmaceuticals Inc. announced the resignation of John Brancaccio, the Chief Financial Officer and a director, effective June 30, 2025, due to personal reasons. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    HEPA
    -24.75%
    Reuters·
    US
    HEPA
    -24.75%

    Hepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEO

    Hepion Pharmaceuticals has appointed Kaouthar Lbiati as interim CEO effective June 16, following the retirement of John Brancaccio for personal reasons. Lbiati, a board member since June 2022, brings over 15 years of leadership experience in biotech and large pharmaceutical companies.

    rttnews·
    US
    HEPA
    -24.75%
    rttnews·
    US
    HEPA
    -24.75%
    © 2025 Longbridge｜Disclaimer